Opinion

Video

Limitations of Conventional Imaging for Assessing Renal Masses

Experts on kidney cancer review challenges associated with limitations of conventional imaging for assessing renal masses and how to potentially improve sensitivity and specificity.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      2 experts are featured in this series.
      Overcoming Challenges for Wider Adoption of TLX250
      1 expert is featured in this series.
      The Impact of Comorbidities, Adherence, and Access on mCRPC Treatment Decisions
      1 expert is featured in this series.
      Formulation Matters: Tailoring Abiraterone Dosing for Optimal Absorption and Tolerability
      2 experts are featured in this series.
      Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging
      Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial
      Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial
      Topline Data From the BOND-003 Trial in NMIBC
      Topline Data From the BOND-003 Trial in NMIBC
      1 expert is featured in this series.
      Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection
      1 expert is featured in this series.
      A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
      3 experts are featured in this series.
      Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
      1 expert is featured in this series.
      Remaining unmet needs in diverse populations with mHSPC
      Related Content
      3d rendered medically accurate illustration of kidney cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      June 6th 2025

      Pivotal trial of histotripsy system for kidney tumors reaches enrollment goal

      Hannah Clarke
      Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.
      Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
      June 19th 2025

      Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

      Amy M. Pearlman, MD
      The conversation covers practical, case-based strategies for counseling MSM patients.
      Jad Chahoud, MD, MPH
      June 5th 2025

      Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

      Benjamin P. Saylor
      ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.
      Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
      June 2nd 2025

      Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

      Amy M. Pearlman, MD
      Medically accurate illustration of kidney cancer | Image Credit: © Crystal light - stock.adobe.com
      June 1st 2025

      Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

      Silas Inman
      "These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.
      Subcutaneous nivolumab approved in EU, Canada for solid tumors
      May 28th 2025

      Subcutaneous nivolumab approved in EU, Canada for solid tumors

      Hannah Clarke
      The approvals are supported by findings from the phase 3 CheckMate-67T trial.
      © 2025 MJH Life Sciences

      All rights reserved.